Cellectis SAALCLS:PAR

9.60
0.01 / 0.10%
2.00k
179.88%
0.2955
Close in EURToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Oct 30 2014 16:35 GMT.

Directors & officers

 NameTitleCompensationAgeOfficer
since
 
AndreChoulika
Chairman of the Board and Chief Executive Officer, Member of the Executive Committee
328.40k EUR
--
1999
Dr. Andre Choulika serves as Chairman of the Board, Chief Executive Officer and Member of the Executive Committee of Cellectis SA as of June 27, 2011. Dr. Choulika specializes in the analysis and use of Meganucleases to modify complex genomes. He has made many of the critical observations in the field and is an author of the patents on the use of Meganucleases in vivo. Dr. Choulika received a Ph.D. in Molecular Virology form University of Paris VI / Institut Pasteur. Dr. Choulika has made post-doctoral studies at the Harvard Medical School within the department of Molecular Medicine of Boston's Children's Hospital.
 
ThierryMoulin
Finance Director
--
--
2014
 
DavidSourdive
Member of the Executive Committee, Executive Vice President - Corporate Development, Director
248.80k EUR
--
2000
 
MathieuSimon
Member of the Executive Committee, Senior Vice President
--
--
2012
 
PhilippeDuchateau
Chief Scientific Officer, Member of the Executive Committee
--
--
2004
 
PhilippeValachs
Company Secretary, Member of the Executive Committee
--
--
2003
 
LaurentArthaud
Director
--
--
--
 
PierreBastid
Director
--
--
--
 
RogerHajjar
Director, representing Kaminvest Holding
--
41
2013
 
AnnickSchwebig
Director
--
--
--
 
AlainGodard
Independent Director
35.88k EUR
--
2008
View all 11 directors & officersOfficers and Directors data as of Oct 26 2014

Director dealings

Mouseover chart for details.
There are no recent director transactions available.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.